Racial, Gender, Socioeconomic Disparities Seen in Teen Alcohol, Drug Screening
Medically reviewed by Drugs.com.
By Lori Solomon HealthDay Reporter
THURSDAY, Oct. 17, 2024 -- Rates of biochemical alcohol and drug screening are disproportionately higher among adolescent trauma patients who are from racial and ethnic minorities, have public or no insurance, or are female, according to a research letter published online Oct. 4 in JAMA Network Open.
Jordan M. Rook, M.D., from the Greater Los Angeles Veterans Administration Healthcare System, and colleagues used the American College of Surgeons (ACS) Trauma Quality Programs dataset (2017 to 2021) to identify 85,362 adolescent trauma patients (aged 12 to 17 years) presenting to 121 ACS-verified pediatric trauma centers. Receipt of biochemical alcohol and drug screening was compared by race.
The researchers found that 24.5 percent of adolescents underwent biochemical alcohol screening, with Black (adjusted odds ratio [aOR], 1.08) and American Indian adolescents (aOR, 2.17) more likely to be screened than White adolescents. Similarly, Hispanic adolescents were more likely to be screened than non-Hispanic adolescents (aOR, 1.20). Screening was also more likely among adolescents who were Medicaid insured (aOR, 1.15) and uninsured (aOR, 1.13) versus those who were privately insured. Female adolescents (aOR, 1.32) were more likely screened than male adolescents. Similar results were seen for biochemical drug screening (21.8 percent screened overall), with higher screening odds seen for adolescents who were Black (aOR, 1.13), American Indian (aOR, 1.75), Hispanic (aOR, 1.20), Medicaid-insured (aOR, 1.28), uninsured (aOR, 1.18), or female (aOR, 1.28).
“Our findings indicate potential disparities in biochemical substance use screening at pediatric trauma centers,” the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-10-18 12:00
Read more
- SABCS: Active Monitoring Noninferior to Guideline Care for Ductal Carcinoma in Situ
- FDA Approves Tryngolza (olezarsen) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome
- Merck’s Investigational Zilovertamab Vedotin in Combination With R-CHP Demonstrates Complete Response Rate of 100% at 1.75 mg/kg Dose in Phase 2 Trial of Previously Untreated Patients With Diffuse Large B-Cell Lymphoma
- Health Span-Lifespan Gaps Widening Globally
- Pressure Ulcers During Spinal Cord Injury Hospitalization Tied to Poor Long-Term Outcomes
- Metformin Beneficial in Lung Cancer Patients With Overweight, Obesity
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions